Mosaic Therapeutics Secures $28 Million for Cancer Research
Mosaic Therapeutics, an innovative oncology therapeutics company based in Cambridge, UK, has successfully secured $28 million in Series A funding, a significant achievement that underscores the growing interest in targeted cancer therapies. The funding round was backed by prominent investors including Syncona Investment Management and Cambridge Innovation Capital. With these financial resources, Mosaic Therapeutics aims to propel its unique pipeline of targeted oncology therapies specifically designed for biomarker-stratified populations. The company has set its sights on advancing its leading programs through various stages of preclinical development and ultimately towards IND-enabling studies, furthering its commitment to finding novel treatments for cancer patients.
At the helm of Mosaic Therapeutics is CEO Brian Gladsden, who previously served as Senior Vice President of Oncology at Novartis.
Under his leadership, the company is leveraging advanced computational methods, merging large dataset mining with experimental approaches. This strategy is aimed at identifying and developing groundbreaking targeted therapies that have the potential to revolutionize drug discovery and enhance treatment precision for cancer patients. A key component of Mosaic’s innovative platform is built on vital research from co-founder Dr. Mathew Garnett’s esteemed Translational Cancer Genomics Laboratory at the Wellcome Sanger Institute. Dr. Garnett, a Senior Group Leader with over two decades of expertise in genomics and cancer therapeutics, has made significant contributions to the field, including the co-discovery of BRAF mutations within cancer cells and identifying the Werner Syndrome helicase as a target in microsatellite instability (MSI) tumors.
Mosaic Therapeutics was co-founded by a distinguished team, comprising Professor Emile Voest and Dr. Adrian Ibrahim, both of whom bring extensive experience and credentials to the company. Professor Voest serves as a Professor of Medical Oncology and holds various prestigious positions, including Chairman of the Board of Cancer Core Europe and Group Leader at the Netherlands Cancer Institute and Oncode Institute. Dr. Ibrahim, who formerly led Technology Translation at the Wellcome Sanger Institute, has dedicated three decades to the discovery and development of cancer and genomics technologies, contributing to numerous successful genomics-focused company spin-outs. Being a spin-out from the Wellcome Sanger Institute grants Mosaic Therapeutics invaluable access to a wealth of scientific expertise, state-of-the-art infrastructure, and vital biological resources, thus enhancing its potential to develop groundbreaking oncological solutions.
They've invested in Mosaic Therapeutics
Get to know these Biotech investors
| Investors | Investment Focus | Startup Investments | Round Size | Connect |
|---|---|---|---|---|
 Syncona Investment Management( ) London  | ||||
 | ||||
| All investors | All investor sectors | All funded startups | All funding rounds |
Click here for a full list of 7,589+ startup investors in the UK